Posted on

Two COVID19 Vaccines Show Promising Results

outbreak coronavirus world 1024x683px 1

the staff of the Ridgewood blog

Ridgewood NJ, two studies were published in The Lancet, describing results of clinical trials for candidate vaccines from China and the UK. The candidate from Chinese pharmaceutical manufacturer CanSino is a single-dose vaccine that utilizes a recombinant adenovirus vector. The associated trial was a randomized, double-blind, placebo-controlled Phase 2 trial that involved 508 healthy human volunteers in Wuhan, China. Two dosages were tested, and both demonstrated high seroconversion after 4 weeks (96% and 97%, respectively) and significant neutralizing antibody response. Severe adverse reactions were reported in 9% of those receiving the higher dose and 1% of those receiving the lower dose, a statistically significant difference. Based on these results, the researchers intend to conduct a Phase 3 trial for the lower vaccine dose in the near future.

Continue reading Two COVID19 Vaccines Show Promising Results